BC
REGN icon

Brookfield Corp’s Regeneron Pharmaceuticals REGN Stock Holding History

Brookfield Corp’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-29,626
Closed -$21.3M – 436
2023
Q2 		$21.3M Buy
29,626
+2,366
+9% +$1.82M 0.08% 87
2023
Q1 		$22.4M Buy
27,260
+9,349
+52% +$7.05M 0.09% 94
2022
Q4 		$12.9M Buy
17,911
+2,886
+19% +$2.13M 0.05% 128
2022
Q3 		$10.3M Buy
+15,025
New +$9.46M 0.04% 154

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Brookfield Corp's REGN Position: Q3 2023 in Review

Brookfield Corp sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 29,626 shares — an estimated $21.3M sold.

Brookfield Corp first reported a position in REGN in Q3 2022 and held it in 4 quarters. The position peaked at $22.4M in Q1 2023. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

  • Brookfield Corp reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Brookfield Corp sold 29,626 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $21.3M.
  • Brookfield Corp first reported a position in Regeneron Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • Brookfield Corp's Regeneron Pharmaceuticals position peaked at $22.4M in Q1 2023.
  • 1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Brookfield Corp's 13F filing for Q3 2023, filed 14 Nov 2023.